Oxybutynin vs Trospium — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Cholinergic Muscarinic Antagonist

Oxybutynin

Brand: OXYTROL

First FDA approval: 1990-09-30

Cholinergic Muscarinic Antagonist

Trospium

First FDA approval: 2010-08-13

Lowest NADACAcquisition cost floor across all NDCs

$0.032Per unit

$0.234Per unit

Average NADACAcross all dosage forms and strengths

$1.01Up to $80.95

$0.728Up to $1.92

Generic manufacturersActive ANDA holders — FDA Orange Book

2139 total ANDAs filed

1011 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$174.7MFull year

$72.4MFull year

Part D claims (CY24)Total fills, all strengths

8.1M2.6M beneficiaries

915K339K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$22Per claim, all NDCs

$79Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

10Minimal friction

4Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

11Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes21 manufacturers

Yes10 manufacturers